Accumulated Pre-Switch Resistance to More Recently Introduced One-Pill-Once-a-Day Antiretroviral Regimens Impacts HIV-1 Virologic Outcome
| Autor: | Karen T. Tashima, Allison DeLong, D’Antuono Matthew, Rebecca Reece, Rami Kantor |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
0301 basic medicine
Adult Male medicine.medical_specialty Human immunodeficiency virus (HIV) HIV Infections Logistic regression medicine.disease_cause Article Drug Administration Schedule 03 medical and health sciences symbols.namesake Young Adult 0302 clinical medicine Virology Internal medicine Antiretroviral Therapy Highly Active Drug Resistance Viral Medicine Humans 030212 general & internal medicine Treatment Failure Fisher's exact test Resistance (ecology) business.industry Mean age Middle Aged Viral Load 030112 virology CD4 Lymphocyte Count Infectious Diseases Treatment success Anti-Retroviral Agents Pill symbols HIV-1 Female business Viral load Tablets |
| Popis: | Background One-pill-once-a-day regimens (OPODs) appeal to providers and patients. The impact of resistance to OPODs in routine clinical care is important yet unclear, particularly in treatment-experienced patients. Objectives We hypothesized that resistance to any OPOD component impacts treatment success and that historical, vs. most recent, resistance better predicts it. Study design In the largest RI HIV Center, we identified all patients starting/switching to Complera/Stribild, evaluated their 12-month viral load (VL) suppression, and examined the impact of demographic, clinical and laboratory data on it, focusing on recent-only vs. accumulated significant resistance, defined as low-, intermediate- or high-level predicted resistance to any OPOD component. Associations with outcomes were evaluated using Fisher exact and Wilcoxon rank sum tests. Hypotheses were tested using logistic regression. Results Of 1624 patients, 224 started/switched to Complera or Stribild, mean age 44 years, 8 years post-diagnosis, CD4 468 cells/μL; 183 treatment-experienced (140 with genotypes; 61% suppressed at switch). Significant OPOD-associated resistance was in 30% by recent-only genotypes, and 38% by all genotypes. 12-month VL suppression was in 83% of treatment-experienced participants: 96% of suppressed at switch, associated with older age, higher CD4, fewer prior genotypes, less accumulated resistance, and better adherence; and 61% of unsuppressed at switch, associated with better adherence. Accumulated resistance independently predicted 12-month failure, better than most-recent resistance only. Conclusion 12-month VL suppression with Complera/Stribild was high, suggesting that OPODs remain options even for experienced patients. Clinicians should consider resistance history before switching to OPODs and continue to focus on improving adherence. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|